Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 0.9% 112.00 1,149,365 16:35:03
Bid Price Offer Price High Price Low Price Open Price
110.00 112.00 112.50 108.00 111.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.06 -20.38 -55.00 63
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:03 O 14,554 112.4999 GBX

Genedrive (GDR) Latest News

More Genedrive News
Genedrive Investors    Genedrive Takeover Rumours

Genedrive (GDR) Discussions and Chat

Genedrive Forums and Chat

Date Time Title Posts
26/2/202102:31Genedrive. A Game Changer for Global Covid 19 Testing Market?5,197
12/2/202108:34Genedrive PLC (GDR) Covid19 Diagnostics930
10/2/202100:21Still waiting....166
28/1/202111:01Genedrive (GDR) One to Watch 944
28/1/202109:42The New Genedrive Thread5

Add a New Thread

Genedrive (GDR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-02-25 18:11:21112.5014,55416,373.24O
2021-02-25 18:07:09112.0017,85019,991.98O
2021-02-25 17:22:34111.258,2169,140.31O
2021-02-25 17:15:00114.5021,82324,987.34O
2021-02-25 17:15:00114.5026,18929,986.41O
View all Genedrive trades in real-time

Genedrive (GDR) Top Chat Posts

Genedrive Daily Update: Genedrive Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 111p.
Genedrive Plc has a 4 week average price of 65.50p and a 12 week average price of 38.50p.
The 1 year high share price is 299p while the 1 year low share price is currently 8.75p.
There are currently 56,474,463 shares in issue and the average daily traded volume is 2,152,470 shares. The market capitalisation of Genedrive Plc is £63,251,398.56.
neo26: Rayj cracks me up..Nothing is certain, nyct and odx got into it early on in the pandemic.Gdr has just got in and hav a partner. The beads are not fda approved but can be used.It will take some months before any meaningful sale numbers come in.It may go down further we cannot predict but what i do know is that within 6 months this will be alot higher than current share price A few ii's are selling hence the price not moving upwards...With this stick put your money in and then forget about it for 6 months. Easily 5 bag from here.All imho
dealit: Patience is needed, I feel March key for GDR share price going North IMHO based on past announcements from the Company.
hazl: Interesting more detail from company available ....note at the end. ' Genedrive Share News (GDR) 4 Buy Sell Share Name Share Symbol Market Type Share ISIN Share Description Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade 20.50 15.77% 150.50 150.00 151.00 163.50 139.50 144.50 1,100,592 08:46:31 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Pharmaceuticals & Biotechnology 1.1 -20.4 -55.0 - 85 Print Alert Genedrive PLC First US shipments of Genedrive(R) 96 SARS-CoV-2 Kit 17/02/2021 7:00am RNS Non-Regulatory TIDMGDR Genedrive PLC 17 February 2021 REACH genedrive plc ("genedrive" or the "Company") First shipments to US of Genedrive(R) 96 SARS-CoV-2 Kit 'genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces the first shipments to the United States of its Genedrive(R) 96 SARS-CoV-2 Kits. Following the Company's announcement on 28 January 2021 confirming genedrive's distribution agreement with Beckman Coulter Life Sciences ("Beckman Coulter"), genedrive can confirm that it has completed its commercial and technical training with the Beckman Coulter sales representatives and has now shipped its first 96 SARS-CoV-2 Kits to the USA. This shipment will allow Beckman Coulter to commence initial sales activities and prepare the market for wider commercial rollout. This shipment coincides with the formal launch of the Genedrive(R) 96 SARS-CoV-2 Kit by Beckman Coulter today.' To learn more about the partnership or to request a quote, Beckman Coulter customers can visit :
sep800: GDR... Been consolidating over the last 2-3 trading days now. MM's stocking up as they hold the share price between 130p - 140p range. Flushing out weak sellers as they continue to accumulate as many shares as possible. Shares in issue very limited hence the huge movements in both directions. Anticipated news will see GDR push through 200 - 250p before pushing back up to 300p plus. Hence why the MM's need shares now. Even if we get just £1 per test, GDR will only need to produce 80M kits to equal its market Cap. But the world requires tens of millions if not Billions of these tests. A M/C of £300m plus is conservative. What would be a huge game changer here is a buy out by one a major pharmaceutical companies. These tests are going to be here for a few years there fore guarantee revenue will continue to push the share price north. ADYOR
oilisgold: Same CEO that let the share price reach 300p knowing well he was doing a placing. I am suprised no legal action has been taken against GDR. I will be forming a small share holder group to take legal action.
bunz3: oilisgold+. you trying so hard to damage this share price people can see through your posting no matter how many posts you post night and day deramping gdr the buyers still loading up as many of them have done their research and read the rns
hooded claw: I still feel GDR is packaged for a takeover.GDR CEO used to work for BC so he knows how they work and what they want.BC is owned by Danaher. Cytiva makes the beads for GDR. Cytiva are owned by Danaher.The only step in the process Danaher don't own is GDR.So GDR will be supplying a Danaher company with product manufactured by a Danaher company. Anyone trying to deramp this is on to a lost cause IMHO
willshh: I'm new to this message board, but saw mention of GDR while looking at posts about Seeing Machines (still waiting for that one)... don't know whether the share is being ramped or not but the company has an interesting product. Conventional covid testing is labour intensive and slow and not particularly accurate (human error), if GDR's kit works and Beckman Coulter obviously thinks it does, it could be very big. Stunning rises in the share price over the last few days would seem to indicate that others think so too. The company's numbers aren't too bad, they have some cash and BC is a good partner. Do your research.
bunz3: even at £10 a share personly might sell any and share price only at £1,30 , seen how ncyt moved up from £2,20 to £12 with the potential here no interest in selling at a low price after this rns Distribution agreement with Beckman Coulter
bunz3: how soon will this share price be a multiple of Todays share price after this rns ,even this part of rns David Budd, CEO of genedrive plc, said: "We are very pleased to have the partnership of Beckman Coulter in accessing significant COVID testing opportunities throughout the United States and Europe, where the incidence of COVID continues to escalate and the need for high throughout testing solutions remains a priority. The combination of genedrive and Beckman Coulter products and expertise provides the Company with a new, innovative, and competitive solution, and a new sales channel for the American market, which we did not have previously. "We are very pleased to now take our initial collaboration and development agreement to the commercial stage. Beckman Coulter is an important and significant company in these core geographies, well suited to promoting, selling, and supporting our products." The Companies are planning commercial introduction of the Genedrive kit from mid February, following commercial and technical training of the Beckman sale and support organisations.
Genedrive share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210226 04:41:16